



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

JPL/SEC/STOCK-CORR-2013-2014/	Date : June 11th, 2018
The National Stock Exchange of India Ltd. Kind Attn.: Mr. Kautuk Upadhyay – Chief Manager Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	
CM Quote : JAGSNPHARM	

**SUBJECT : COMPLIANCE AS PER REGULATION 33 OF THE SEBI (LISTING
OBLIGATION AND DISCLOSURE REQUIREMENT) REGULATIONS, 2015.**

Sir/Madam,

This is in response to your e-mail, on the subject noted above.

In this connection, this is to inform you we have submitted information / clarification / prayer in matter through NEAPS on 04.06.2018 under head Announcements as suggested by Mr. Yogesh deshमुख under the link NEAPS > Compliance > Results Adequacy and Accuracy path the was not access due to some technical reason or any other issue in server.

Once again we are trying to submit the on the following path if we access the same:

NEAPS > Compliance > Results Adequacy and Accuracy, with a request please close the same and take the same on records.

We sincerely trying to do the things before time and never intent to delay or violate any norms.

Kindly see our past record.

Thanking you,

Yours faithfully,

For JAGSONPAL PHARMACEUTICALS LTD.,


(R. K. KAPOOR)
COMPANY SECRETARY.





JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

JPL/SEC/STOCK-CORR-2013-2014/	Date : June 4th, 2018
The National Stock Exchange of India Ltd. Kind Attn.: Mr. Kautuk Upadhyay – Chief Manager Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	
CM Quote : JAGSNPHARM	

**SUBJECT : COMPLIANCE AS PER REGULATION 33 OF THE SEBI (LISTING
OBLIGATION AND DISCLOSURE REQUIREMENT) REGULATIONS, 2015.**

Sir/Madam,

This is In response to your e-mail, this is to inform you that due to heavy traffic on neaps we were not able to access. This is minor delay and is not intentional.

We did the same thing with BSE before time. (A copy of the same is attached herewith for your reference)

- The figure of the last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figure upto the third quarter of the respective financial year.
- There is no change in equity as is evident from the assets and liabilities statement annexed.

Results are as per the latest format available on SEBI Circular. IF THERE IS ANY DEVIATION PLEASE SUGGEST AND WE SHALL ABIDE BYE YOUR SUGGESTION.

Sir, you are requested to take lenient view and don't put any harsh penal provisions. This is our humble request.

We sincerely try to do the things before time and never intent to delay or violate any norms.

Kindly see our past record.

Thanking you,

Yours faithfully,
For **JAGSONPAL PHARMACEUTICALS LTD.,**

(R. K. KAPOOR)
COMPANY SECRETARY.

NSE/LIST/FR/6825

31-May-2018

The Company Secretary,
Jagsonpal Pharmaceuticals Limited
T-210-J, Shahpur Jat
null
NEW DELHI-110049 .

Sub: Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is with reference to Regulation 33 and Regulation 97 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding submission of financial results by listed entities and monitoring of Adequacy/Accuracy of the Disclosures submitted by the listed entities for the period ended March 2018.

Following deficiency/ies have/has been observed in your financial result, you are requested to kindly clarify on below mentioned points:

1. Standalone Reconciliation of Equity not submitted
2. Financial results submitted is not as per format prescribed by SEBI

In view of the above, you are requested to provide explanation to the Exchange within 5 working days from the date of the letter in respect of the above non-compliance/s, on the following path:
Path – NEAPS > Compliance > Result Adequacy and Accuracy

In case of any further queries you may contact the following;
Yogesh Deshmukh, Ritu Farsaiya, Joyce Rodrigues- 022-26598236/31

Yours faithfully,
For National Stock Exchange of India Ltd.

Kautuk Upadhyay
Chief Manager

This Document is Digitally Signed